Welcome to Cora · $15 off your first month · use CORA15 at checkout→
24/7 Messaging SupportLegitScript-Certified100% OnlineUS-Licensed PharmaciesFree ShippingProvider Review in 24 HoursHSA/FSA Accepted24/7 Messaging SupportLegitScript-Certified100% OnlineUS-Licensed PharmaciesFree ShippingProvider Review in 24 HoursHSA/FSA Accepted
Blog › Safety
Safety · 14 min read · Jan 25, 2026

Semaglutide & Tirzepatide Side Effects: Complete Guide to Contraindications

Wegovy® and Zepbound® label side effects, boxed warning and contraindications, plus STEP 1 and SURMOUNT-1 trial data. Compounded versions are not FDA-approved.

Quick answer

The most common side effects of the FDA-approved GLP-1 weight-management medicines are gastrointestinal, and they are most frequent while the dose is being increased. In the Wegovy® prescribing information, adults on Wegovy® (semaglutide) 2.4 mg in three pooled placebo-controlled weight-reduction trials of up to 68 weeks reported nausea (44% vs 16% on placebo), diarrhea (30% vs 16%), vomiting (24% vs 6%) and constipation (24% vs 11%). In the Zepbound® prescribing information, adults on Zepbound® (tirzepatide) 5, 10 or 15 mg in two pooled placebo-controlled weight-reduction trials of up to 72 weeks (ranges across the three doses) reported nausea (25%–29% vs 8% on placebo), diarrhea (19%–23% vs 8%), vomiting (8%–13% vs 2%) and constipation (11%–17% vs 5%). Both labels carry a boxed warning for thyroid C-cell tumors and describe serious risks including pancreatitis and gallbladder disease; contact your provider promptly for severe or persistent symptoms. These figures come from trials of the FDA-approved brands, and rates from different drugs' trials cannot be directly compared. Compounded semaglutide and compounded tirzepatide are not FDA-approved, and their side-effect rates have not been measured in equivalent trials.

Medically Reviewed

Michael Wasef, MD

Board-certified internal medicine · Wasef Health, PC · Last reviewed: May 12, 2026

Editor's note: Michael Wasef, MD, medically reviewed an earlier version of this article (last reviewed May 12, 2026). Since that review, the Cora Health content team updated the Sources & verification list and, in October 2026, replaced the opening section; rewrote the summary at the top and the two label side-effect sections (now drawn from the FDA-approved Wegovy® and Zepbound® labels); corrected trial figures and their attribution using the published STEP 1 and SURMOUNT-1 results; rewrote the serious-warnings section (boxed-warning quotation and source, serious-risks list, a note that the suicidal-ideation warning was removed from both labels, and the closing paragraph on serious adverse events); corrected the contraindications section; and revised wording in the tips and when-to-call sections. The team also updated the page description, the FDA compounding quotation and context in the trial-figures section, the author byline and related-reading links. Those revisions have not been medically reviewed.

Written by

Cora Health Content Team

What are the most common GLP-1 side effects?

The most common side effects of the FDA-approved weight-management medicines Wegovy® (semaglutide), a GLP-1 receptor agonist, and Zepbound® (tirzepatide), a GIP and GLP-1 receptor agonist, are gastrointestinal: nausea, diarrhea, vomiting, constipation and abdominal pain. Both labels direct gradual dose escalation to reduce the risk of gastrointestinal adverse reactions. The lists below describe the FDA-approved brands; they do not establish side-effect rates for compounded medications. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider.

The Wegovy® label (Novo Nordisk, revised June 2026) lists these as the most common adverse reactions (incidence ≥5% in adults or pediatric patients aged 12 years and older), across the label’s doses including 7.2 mg:

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Dysesthesia (abnormal skin sensations)
  • Headache
  • Fatigue
  • Dyspepsia (indigestion)
  • Dizziness
  • Abdominal distension
  • Eructation (burping)
  • Hypoglycemia in patients with type 2 diabetes
  • Flatulence
  • Gastroenteritis
  • Gastroesophageal reflux disease
  • Hair loss

The Zepbound® label (Eli Lilly, revised August 2026) lists these as the most common adverse reactions, reported in at least 5% of patients:

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Dyspepsia (indigestion)
  • Injection site reactions
  • Fatigue
  • Hypersensitivity reactions
  • Eructation (burping)
  • Hair loss
  • Gastroesophageal reflux disease

Both labels carry a boxed warning for the risk of thyroid C-cell tumors. Semaglutide and tirzepatide caused thyroid C-cell tumors in rodents, and it is unknown whether Wegovy® or Zepbound® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Both labels contraindicate use in people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in people with a known serious allergy (hypersensitivity) to the medicine or any of its ingredients, including anyone who has had a serious allergic reaction to it. Tell your prescribing provider about any personal or family history of thyroid cancer or MEN 2, and about any serious allergic reaction, before starting treatment. Serious problems the labels describe include severe stomach problems, pancreatitis, gallbladder disease, low blood sugar (especially in people with type 2 diabetes who also take insulin or a sulfonylurea), kidney problems from dehydration, serious allergic reactions, vision changes in people with type 2 diabetes, a faster resting heart rate (Wegovy®), and food or liquid getting into the lungs during surgery or deep sedation (tell every provider before a procedure). Both labels tell patients to stop the medicine and contact their healthcare provider promptly if pancreatitis is suspected (severe stomach-area pain that will not go away, sometimes spreading to the back, with or without vomiting), and to stop the medicine and seek medical advice promptly for signs of an allergic reaction. For trouble breathing or swallowing, or swelling of the face, lips, tongue or throat, seek emergency care. Contact the prescribing provider for other severe or persistent symptoms, including nausea, vomiting or diarrhea that does not go away. These lists come from the FDA-approved brand labels. Compounded semaglutide and compounded tirzepatide are not FDA-approved, and their side-effect rates have not been measured in equivalent trials. For brand-label dosing facts and who sets a compounded dose, see the Wegovy® label dosage chart and Zepbound® label dosage chart.

Side effect rates in the Wegovy® and Zepbound® pivotal trials

The Phase III trials behind the FDA-approved brands, published in the New England Journal of Medicine, reported these adverse-event rates (drug vs placebo). Trial rates may not reflect rates seen in practice, and adverse-event rates from different drugs' trials cannot be directly compared.

Wegovy® (semaglutide 2.4 mg) vs placebo — from STEP 1 (Wilding et al., NEJM 2021), 1,961 participants (1,306 Wegovy®, 655 placebo); adults with obesity, or overweight with at least one weight-related condition, without diabetes; 68 weeks; with lifestyle intervention:

  • Nausea: 44.2% (vs 17.4% placebo)
  • Diarrhea: 31.5% (vs 15.9% placebo)
  • Vomiting: 24.8% (vs 6.6% placebo)
  • Constipation: 23.4% (vs 9.5% placebo)
  • Treatment discontinuation due to adverse events: 7.0% (vs 3.1% placebo)
  • Serious adverse events: 9.8% (vs 6.4% placebo); the difference was mainly due to serious gastrointestinal (1.4% vs 0%) and hepatobiliary (1.3% vs 0.2%) disorders

Zepbound® (tirzepatide) 15 mg vs placebo — from SURMOUNT-1 (Jastreboff et al., NEJM 2022), 2,539 participants across the 5, 10 and 15 mg and placebo arms (630 on 15 mg, 643 on placebo); adults with obesity, or overweight with at least one weight-related condition, without diabetes; 72 weeks; with lifestyle intervention:

  • Nausea: 31.0% at 15 mg dose (vs 9.5% placebo)
  • Diarrhea: 23.0% at 15 mg dose (vs 7.3% placebo)
  • Vomiting: 12.2% at 15 mg dose (vs 1.7% placebo)
  • Constipation: 11.7% at 15 mg dose (vs 5.8% placebo)
  • Treatment discontinuation due to adverse events: 6.2% at 15 mg dose (vs 2.6% placebo)

Critical context: these figures reflect studies of the FDA-approved branded products only, and adverse-event rates from different drugs' trials cannot be directly compared. Per the U.S. Food and Drug Administration, "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" (FDA — Compounding and the FDA: Questions and Answers). Compounded medications are not therapeutically equivalent to FDA-approved products. Side effect rates for compounded semaglutide and compounded tirzepatide have not been formally measured in equivalent trials. Individual results vary.

Common Side Effects on the Wegovy® (semaglutide) Label

The Wegovy® label lists these among the most common adverse reactions in adults (percentages from three pooled placebo-controlled weight-reduction trials of Wegovy® 2.4 mg, of up to 68 weeks) and says gastrointestinal reactions were most frequently reported during dosage escalation. Compounded semaglutide is not FDA-approved and its side-effect rates have not been measured in equivalent trials.

  • Nausea — 44% on Wegovy® 2.4 mg (vs 16% on placebo)
  • Diarrhea — 30% on Wegovy® 2.4 mg (vs 16% on placebo)
  • Vomiting — 24% on Wegovy® 2.4 mg (vs 6% on placebo)
  • Constipation — 24% on Wegovy® 2.4 mg (vs 11% on placebo)
  • Abdominal pain — 20% on Wegovy® 2.4 mg (vs 10% on placebo)
  • Headache — 14% on Wegovy® 2.4 mg (vs 10% on placebo)
  • Fatigue — 11% on Wegovy® 2.4 mg (vs 5% on placebo)
  • Dyspepsia (indigestion) — 9% on Wegovy® 2.4 mg (vs 3% on placebo)
  • Dizziness — 8% on Wegovy® 2.4 mg (vs 4% on placebo)
  • Eructation (burping) — 7% on Wegovy® 2.4 mg (vs less than 1% on placebo)

Common Side Effects on the Zepbound® (tirzepatide) Label

Zepbound® (tirzepatide) acts on both GIP and GLP-1 receptors. As with Wegovy®, the most common adverse reactions on its label are gastrointestinal; adverse-reaction rates from different drugs' trials cannot be directly compared. The Zepbound® label says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. Compounded tirzepatide is not FDA-approved and its side-effect rates have not been measured in equivalent trials. The Zepbound® label lists these among its most common adverse reactions (percentages from two pooled placebo-controlled weight-reduction trials of Zepbound® 5, 10 and 15 mg, of up to 72 weeks; ranges across the three doses):

  • Nausea — 25%–29% on Zepbound® 5–15 mg (vs 8% on placebo)
  • Diarrhea — 19%–23% on Zepbound® 5–15 mg (vs 8% on placebo)
  • Vomiting — 8%–13% on Zepbound® 5–15 mg (vs 2% on placebo)
  • Constipation — 11%–17% on Zepbound® 5–15 mg (vs 5% on placebo)
  • Abdominal pain — 9%–10% on Zepbound® 5–15 mg (vs 5% on placebo)
  • Dyspepsia (indigestion)
  • Injection site reactions
  • Fatigue
  • Hypersensitivity reactions
  • Eructation (burping)
  • Hair loss
  • Gastroesophageal reflux disease

Serious Warnings and Black Box Alerts

The Wegovy® and Zepbound® labels carry a boxed warning regarding thyroid C-cell tumors. The Wegovy® prescribing information (June 2026), Boxed Warning, states:

"In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. WEGOVY® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."

(Source: Wegovy® prescribing information (June 2026), Boxed Warning; cross-references omitted.) The Zepbound® label carries the equivalent boxed warning for tirzepatide.

Other serious risks documented in the FDA-approved labels include:

  • Acute pancreatitis — stop the medicine and contact your provider if suspected; symptoms may include persistent or severe abdominal pain, sometimes spreading to the back, with or without nausea or vomiting.
  • Acute kidney injury — often secondary to dehydration from GI side effects; particularly relevant in patients with pre-existing renal disease.
  • Serious hypersensitivity reactions — including anaphylaxis and angioedema.
  • Diabetic retinopathy complications — primarily documented in type 2 diabetes patients with pre-existing retinopathy.
  • Acute gallbladder disease — cholelithiasis and cholecystitis reported in clinical trials.

Earlier versions of the Wegovy® and Zepbound® labels included a warning about suicidal behavior and ideation; it was removed from both labels in early 2026. Contact your provider promptly about any mood changes or thoughts of self-harm.

Serious adverse events occurred in these trials; how often depends on the event and the study. The current prescribing information lists the warnings and reported rates. Compounded medications are not FDA-approved and have not been independently evaluated for these specific safety signals at trial scale; serious adverse event rates for compounded versions are not formally measured.

Contraindications and cautions

The Wegovy® and Zepbound® labels list two contraindications. The licensed provider who reviews your assessment screens your health history for these contraindications. Cora Health does not prescribe; licensed providers make all clinical decisions.

  • Personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known serious hypersensitivity to the medicine or any of its ingredients
  • Other situations your provider weighs
    • Pregnancy — the Wegovy® label directs stopping at least 2 months before a planned pregnancy; both labels direct stopping when pregnancy is recognized.
    • Severe gastroparesis — not recommended on either label.
    • History of pancreatitis.
    • Kidney disease.
    • Use of another GLP-1 medicine.

Practical Tips for Managing Side Effects

Most GI side effects are manageable with lifestyle adjustments. These general strategies may help with discomfort; ask your provider which apply to you:

  • Eat smaller, more frequent meals — avoid large portions that overwhelm your slowed gastric emptying
  • Stay well-hydrated — sip water throughout the day, especially if experiencing vomiting or diarrhea
  • Avoid high-fat, greasy, or spicy foods in the first weeks of treatment
  • Inject on a consistent day and time each week
  • Ask your provider about anti-nausea options (e.g., ginger supplements, prescription ondansetron) if nausea is severe
  • Do not rush dose escalation; both labels direct gradual dose escalation to reduce the risk of gastrointestinal side effects
  • Avoid lying down immediately after eating

When to Contact Your Provider Immediately

While most side effects are mild, certain symptoms require prompt medical attention. Contact the licensed provider managing your care, or seek emergency care, if you experience:

  • Severe or persistent abdominal pain, with or without pain spreading to the back or vomiting (possible pancreatitis)
  • Persistent vomiting that prevents you from keeping down fluids
  • Signs of allergic reaction: rash, swelling of the face or throat, difficulty breathing
  • Vision changes
  • Signs of dehydration: dizziness, dark urine, rapid heartbeat
  • Thoughts of self-harm, for any reason: contact your provider, or call or text 988, right away
  • A lump or swelling in the neck, hoarseness, or trouble swallowing

Sources & verification

All side-effect prevalence figures, contraindications, and boxed-warning language in this article are sourced from FDA-approved prescribing information and peer-reviewed Phase III clinical trials published in the New England Journal of Medicine. Label figures verified against the Wegovy® (June 2026) and Zepbound® (August 2026) prescribing information on October 16, 2026.

  • Original 2021 Wegovy® approval label (superseded; the current label is listed in these sources): accessdata.fda.gov (PDF)
  • Original 2023 Zepbound® approval label (superseded; the current label is listed in these sources): accessdata.fda.gov (PDF)
  • 2020 Ozempic® (semaglutide for type 2 diabetes) label (superseded by later revisions): accessdata.fda.gov (PDF)
  • FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  • STEP 1 (Wilding et al., NEJM 2021): mean body-weight change was −14.9% with FDA-approved Wegovy® (semaglutide) 2.4 mg vs −2.4% with placebo at 68 weeks in adults with obesity, or overweight with at least one weight-related condition, without diabetes, with lifestyle intervention. Individual results vary. These trials studied the FDA-approved products, not compounded medications. Full adverse event profile in supplementary appendix: nejm.org/doi/full/10.1056/NEJMoa2032183
  • SURMOUNT-1 (Jastreboff et al., NEJM 2022): mean body-weight change with FDA-approved Zepbound® (tirzepatide) 15 mg vs placebo at 72 weeks in adults with obesity, or overweight with at least one weight-related condition, without diabetes, with lifestyle intervention, was −20.9% vs −3.1% (treatment-regimen estimand). Individual results vary. For the efficacy estimand, mean body-weight change was −22.5% vs −2.4%. Individual results vary. These trials studied the FDA-approved products, not compounded medications. Full adverse event profile in supplementary appendix: nejm.org/doi/full/10.1056/NEJMoa2206038
  • CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
  • FDA Adverse Event Reporting System (FAERS) — public dashboard for adverse event reports for any drug, including post-market surveillance signals: fda.gov FAERS public dashboard
  • Cora Health Compounded vs Brand-Name GLP-1 Comparison (internal sister article): /blog/compounded-vs-brand-glp1
  • Cora Health 2026 GLP-1 Telehealth Industry Report (12-provider pricing and methodology): /blog/cora-2026-glp1-industry-report
  • Novo Nordisk — Wegovy® prescribing information, revised June 2026: novo-pi.com/wegovy.pdf
  • Eli Lilly — Zepbound® prescribing information, revised August 2026: pi.lilly.com/us/zepbound-uspi.pdf

Cora Health Content Team

Written by the Cora Health content team. This article was medically reviewed by Michael Wasef, MD, a board-certified internal medicine physician at Wasef Health, PC, for clinical accuracy and compliance with current guidelines. Sections revised after the review date are not covered by that review; see the editor's note at the top of this article. Compounded medications are not FDA-approved.

Related reading

View Cora Health plans →Tirzepatide side effects →Important safety information →Compounded vs brand-name GLP-1 comparison →GLP-1 cost calculator →

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new medication or treatment. Cora Health does not prescribe medication; licensed providers at Wasef Health, PC review every patient assessment and prescribe only when clinically appropriate.

Ozempic®, Wegovy®, Mounjaro®, Zepbound® and other brand names are registered trademarks of their respective owners; Cora Health is not affiliated with Novo Nordisk or Eli Lilly.

Ready to start?

Begin your wellness journey today

Personalized wellness plans from licensed providers. Free shipping. 100% online.

See If You Qualify
← Back to all articles